About the report
Warfarin is a common drug that is prescribed to treat blood clots such as deep vein thrombosis and pulmonary embolism. It is also used to prevent stroke in people who have atrial fibrillation, valvular heart disease or artificial heart valves. It is also known by its brand name Coumadin.
You can take this information with you on your next routine visit to your physician and understand how your genetics influences the way you metabolize Warfarin.
In 2007, the US Food and Drug Administration (FDA) mandated that information about the genes CYP2C9 and VKORC1 be included in the labeling information on Warfarin. In 2010, the FDA updated the drug’s label to include specific dosage recommendations. Genetic testing for Warfarin dosage will look at specific variants in CYP2C9 and VKORC1 genes and deduce the individual’s ability to metabolize the drug.
Researchers from the Mayo Clinic and Medco Health Solutions, Inc., presented the results of their study involving genetic testing to guide the dosing of Warfarin. According to the results of the study, there were 31% reduction in the number of hospitalizations within 6 months of beginning warfarin therapy in individuals who took genetic testing as compared to those who did not. In addition to this the study also observed that was a 28% drop in hospital admissions arising due to bleeding complications.
According to Dr. Robert Epstein, the lead author of the study, warfarin represents a good example for using genetic testing for increasing the efficacy of this almost 60 year old drug. With anywhere between 2005 and 2015, the number of warfarin prescriptions have ranged between 10 to 40 million a year.
You can now upload your DNA raw data from 23andMe, Ancestry DNA, Family Tree DNA, Living DNA or My Heritage to get a free warfarin report that you can take along to your next routine visit to your clinic.
Important note: Your report may not contain all of the traits listed here depending upon the number of markers present in your raw data file.